Patents Examined by Irina Neagu
  • Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
    Patent number: 10640464
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers and/or activity modifiers.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: May 5, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Treatment for therapy refractory depression
    Patent number: 10603297
    Abstract: A method treats patient with treatment resistant depression, adjunct to standard antidepressant treatment or as monotherapy. These patients will be identified by non-response to at least one pharmacological antidepressant treatment with a sufficient dose and over a sufficient period of time. Further, one embodiment of the method includes a procedure to identify patients who would benefit from a combination of standard antidepressants with the described compounds from the start of the treatment in order to maximize the likelihood of response. Another embodiment of the method combines the described compounds with forms of Magnesium salts in order to overcome longer term tolerability issues with the compounds.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: March 31, 2020
    Inventor: Harald Murck
  • Multi-API loading prodrugs
    Patent number: 10584099
    Abstract: The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: March 10, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Laura Cook Blumberg
  • Compositions and methods for increasing efficiency of cardiac metabolism
    Patent number: 10556013
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 11, 2020
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
    Patent number: 10550122
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including Pl3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: February 4, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
  • Oral suspension comprising telmisartan
    Patent number: 10537523
    Abstract: A drinkable pharmaceutical solution includes telmisartan or a pharmaceutically acceptable salt, hydrate or polymorph thereof, where the telmisartan has a concentration of 1 to 10 mg/ml within the drinkable pharmaceutical solution, and the drinkable pharmaceutical solution has a pH of 10.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 21, 2020
    Inventors: Detlef Mohr, Stefan Lehner
  • Quinolone-3-diarylethers
    Patent number: 10532983
    Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 14, 2020
    Assignee: Oregon Health & Science University
    Inventors: Michael Riscoe, Aaron Nilsen, Galen Miley, Rolf Winter, Sovitj Pou, Jane Xu Kelly, Rozalia Dodean
  • Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
    Patent number: 10532038
    Abstract: The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: January 14, 2020
    Assignees: FUNDACÍON CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC), HOSPITAL CLÍNIC DE BARCELONA
    Inventors: Borja Ibáñez Cabeza, Ana García-Álvarez, Valentín Fuster Carulla
  • (R)-pirlindole and its pharmaceutically acceptable salts for use in medicine
    Patent number: 10533012
    Abstract: (R)-pirlindole or its pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising the same for use in the therapeutic treatment and prevention of pain.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 14, 2020
    Assignee: TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
    Inventors: Augusto Eugénio Pardal Filipe, Pedro Filipe Eufrásio Pedroso, Susana Marques Almeida Pecorelli, Carlos Alberto Eufrásio Casimiro Caixado, Ana Sofia da Conceição Lopes, João Carlos Ramos Damil
  • Abuse-deterrent drug formulations
    Patent number: 10525052
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: January 7, 2020
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Klibanov
  • Methods of generating beta-lactamase resistant carbapenem compounds
    Patent number: 10519161
    Abstract: The present invention includes compositions, methods of making and using novel carbapenem compounds including active agents, compounds, antibacterial agents, pharmaceutically acceptable salts of C1?-C1? di-substituted carbapenem compounds, C5? substituted carbapenem compounds, C6?-C6? di-substituted carbapenem compounds and combinations thereof.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: December 31, 2019
    Assignee: Southern Methodist University
    Inventor: John D. Buynak
  • Covalent small molecule DCN1 inhibitors and therapeutic methods using the same
    Patent number: 10500194
    Abstract: Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: December 10, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Jianfeng Lu, Liu Liu, Jeanne Stuckey, Liangyou Rui, Yi Sun
  • Methylnaltrexone nasal formulations, methods of making, and use thereof
    Patent number: 10485798
    Abstract: Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: November 26, 2019
    Assignee: APTAPHARMA INC.
    Inventor: Siva Rama K. Nutalapati
  • In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
    Patent number: 10477862
    Abstract: The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: November 19, 2019
    Assignee: Ecolab USA Inc.
    Inventors: Junzhong Li, David D. McSherry, Richard Staub
  • Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
    Patent number: 10450295
    Abstract: This invention relates to methods of reversing and inhibiting liver fibrosis and hepatitis using a small indolinone molecule Hesperadin and related compounds. Methods of identifying such agents and using them to inhibit the expression of collagens and ECM proteins including MMPs and TIMPs in purified hepatic stellate cells are provided. In vivo data of Hesperadin in inhibiting induced collagen production are presented. This method of specifically targeting drugs to hepatic stellate cells in vivo, provides a novel therapy for liver diseases.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: October 22, 2019
    Assignee: Acclaim BioMed USA LLC
    Inventors: Kenneth Ka-Ho Lee, Stanton Hon-Lung Kok, Tsz-Wai Kok, Sing-Wan Wong, John Yeuk-Hon Chan
  • Sorafenib derivatives as p21 inhibitors
    Patent number: 10449182
    Abstract: The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: October 22, 2019
    Assignee: The Regents of the University of California
    Inventors: Robert H. Weiss, Bruce D. Hammock, Hiromi Inoue Wettersten, Sung Hee Hwang
  • Pharmaceutical composition containing Ginkgolide B and blood platelet prostaglandin cyclooxygenase inhibitor and method for preparation thereof and use thereof
    Patent number: 10441599
    Abstract: Provided is a pharmaceutical composition containing ginkgolide B and the blood platelet prostaglandin cyclooxygenase inhibitor aspirin, a method for preparation of the pharmaceutical composition and a use thereof. When used together, ginkgolide B and aspirin have a synergistic effect in resisting platelet aggregation.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: October 15, 2019
    Assignee: CHENGDU BAIYU PHARMACEUTICAL CO., LTD
    Inventor: Yi Sun
  • Compounds
    Patent number: 10435391
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 8, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
  • Crystalline forms of darunavir
    Patent number: 10407438
    Abstract: The present invention relates to novel crystalline forms of darunavir, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Chiajen Lai, Bing Shi
  • Methods and compositions to treat cancer
    Patent number: 10391084
    Abstract: Embodiments provided herein relate to methods and compositions for treating cancer. Some embodiments include treating lung cancers and renal cancers.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: August 27, 2019
    Assignee: Children's Hospital Medical Center
    Inventors: Jeffrey Whitsett, Yutaka Maeda